SPARC gene variants predict clinical outcome in locally advanced and metastatic pancreatic cancer patients

Citation metadata

From: Medical Oncology(Vol. 34, Issue 8)
Publisher: Springer
Document Type: Report
Length: 357 words

Document controls

Main content

Abstract :

To access, purchase, authenticate, or subscribe to the full-text of this article, please visit this link: http://dx.doi.org/10.1007/s12032-017-0993-3 Byline: Cristina Arqueros (1), Juliana Salazar (2,3), M. J. Arranz (4), Ana Sebio (1), Josefina Mora (5), Ivana Sullivan (1), Maria Tobena (1), Marta Martin-Richard (1), Agusti Barnadas (1), Montserrat Baiget (2), David Paez (1) Keywords: SPARC; Pancreatic cancer; Polymorphisms; Biomarker; Prognosis; Nab-paclitaxel Abstract: Secreted protein acidic and rich in cysteine (SPARC) is a glycoprotein of the extracellular matrix whose expression can be altered in malignant pancreatic cells and in the adjacent stromal fibroblasts. We evaluated the possible role of SPARC gene variants as prognostic markers for locally advanced and metastatic pancreatic cancer. We analyzed eight tagging single-nucleotide polymorphisms (TagSNPs) in the SPARC gene in 74 patients with pancreatic ductal adenocarcinoma treated with chemotherapy alone or combined with radiotherapy. TagSNPs were chosen using the HapMap genome browser and Haploview software 4.2 based on two predefined criteria: (1) coefficient cutoff of 0.80 and (2) minor allele frequency (MAF) a[yen] 0.10. Univariate analyses revealed significant associations between four SNPs (rs17718347, rs2347128, rs3210714, and rs967527) and PFS. The rs3210714 genetic variant was also associated with OS. In the multivariate analyses, rs17718347 (HR 0.4 95% CI 0.2--0.8 p = 0.013) and rs2347128 (HR 0.5 95% CI 0.3--0.9 p = 0.049) remained statistically associated with PFS. In addition, patients harboring the T-A-G haplotype (rs17718347, rs1978707, rs2347128) had a better PFS (p = 0.002). Our findings suggest that SPARC polymorphisms may be useful in predicting outcome in patients with locally advanced and metastatic pancreatic cancer. Author Affiliation: (1) Department of Medical Oncology, Hospital de la Santa Creu i Sant Pau, Universitat AutA[sup.2]noma de Barcelona, C/Sant Quinti, 89, 08026, Barcelona, Spain (2) Department of Genetics, Hospital de la Santa Creu i Sant Pau, Universitat AutA[sup.2]noma de Barcelona, Barcelona, Spain (3) CIBERER U-705, Barcelona, Spain (4) Fundacio Docencia i Recerca Mutua Terrassa, Terrassa, Spain (5) Department of Biochemistry, Hospital de la Santa Creu i Sant Pau, Universitat AutA[sup.2]noma de Barcelona, Barcelona, Spain Article History: Registration Date: 01/07/2017 Received Date: 02/03/2017 Accepted Date: 01/07/2017 Online Date: 07/07/2017 Article note: Cristina Arqueros and Juliana Salazar contributed equally to this study.

Source Citation

Source Citation   

Gale Document Number: GALE|A497912897